#Italy #Milan #Hepatitis Delta #EIT Pharma #Lonafarnib

EIT Pharma to Showcase Innovations at the 2026 Delta Cure International Meeting

EIT Pharma, Inc., a forward-thinking biotechnology company specializing in treatments for infectious diseases, will be a key sponsor and presenter at the 5th Edition of the Delta Cure International Meeting, taking place on October 15-16, 2026, in the picturesque city of Milan, Italy.

This highly regarded conference represents a premier global platform focusing on the Hepatitis Delta Virus (HDV) and offers a comprehensive array of discussions on its epidemiology, virology, immunology, and clinical management. EIT Pharma’s participation underscores its commitment to advancing treatment options for chronic Hepatitis Delta (CHD), a notably challenging condition arising in patients already infected with Hepatitis B.

Presentation Highlights

During this event, EIT Pharma will unveil new data from its promising lonafarnib development program aimed at treating CHD. Notably, lonafarnib stands out as the only oral therapy currently in advanced stages of clinical testing for this condition.

Oral Presentation

• - Title: Histologic Improvement and Reduction in Necroinflammation with Lonafarnib-Based Therapy in Chronic Hepatitis Delta Phase 3 D-LIVR Trial
• - Presenter: Dr. Nancy Reau, Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center
• - Date: Friday, October 16, 2026, 12:00 PM CEST
• - Poster Number: 104

Breakfast Briefing

• - Title: Sunrise on Lonafarnib EIT Pharma Breakfast Briefing
• - Date: Friday, October 16, 2026, 7:00 AM CEST

Poster Presentations

EIT Pharma will also present additional research through posters:

• - Poster 105: Post-treatment response following 48 weeks of lonafarnib therapy; presented by Dr. Saeed Hamid.
• - Poster 106: Clinical significance of ALT dynamics following lonafarnib treatment cessation; presented by Dr. Ohad Etzion.

The Potential of Lonafarnib

Lonafarnib is an investigational oral therapy designed to inhibit a critical point in the lifecycle of the hepatitis D virus. As the first oral candidate for treating CHD in late-stage clinical trials, its inclusion in the FDA’s New Drug Application process reflects its potential to address a pressing medical need. However, it’s essential to note that lonafarnib's safety and efficacy are still being evaluated, and it has not received approvals from the FDA or other regulatory authorities.

About EIT Pharma

Founded with a mission to transform the landscape of infectious disease treatment, EIT Pharma is dedicated to scientific rigor and patient-centered approaches. The company is building a robust portfolio aimed at tackling significant unmet medical needs in infectious diseases.

EIT Pharma emphasizes not just innovation but also the real-world impact of its therapies, continually striving to translate scientific breakthroughs into effective health solutions for patients in desperate need.

As the 2026 Delta Cure International Meeting approaches, EIT Pharma stands at the forefront of hope for many living with chronic hepatitis delta, reflecting its unwavering commitment to pioneering better therapies for serious infectious diseases.

Closing Thoughts

In a world where infectious diseases pose a significant challenge to global health, events like the Delta Cure Meeting and initiatives by companies like EIT Pharma signify the progress being made. The insights gathered here could pave the way for groundbreaking advancements in the fight against hepatitis delta, ultimately leading to improved patient outcomes. As the industry converges in Milan, anticipation mounts for the promising revelations that will surely emerge from EIT Pharma’s presentations.